Association Between Sleep Duration and Glycemic Control Among Patients with Type 2 Diabetes Mellitus in India

2014 ◽  
Vol 9 (1) ◽  
pp. 22-28
Author(s):  
Anil C Mathew ◽  
Elvin Benny ◽  
Jenit A Osborn ◽  
Senthil Kumar Rajasekaran ◽  
Suresh R Prabu ◽  
...  
2019 ◽  
Vol 2019 ◽  
pp. 1-8 ◽  
Author(s):  
Wagner Martorina ◽  
Almir Tavares

Aims. Sleep duration (SD) has been associated with metabolic outcomes. Is there an independent association between short/long SD and glycemic control (GC) in type 2 diabetes mellitus (T2DM) outpatients, compared to intermediate SD? Employing up-to-date definitions of SD, we comprehensively considered, simultaneously, all known confounding/mediating factors that recently emerged in the literature: age, gender, diet, physical activity, obesity, night pain, nocturnal diuresis, sleep quality, chronotype, sleep apnea, depressive symptoms, alcohol, caffeine, tobacco, number of endocrinologist appointments, T2DM family history, and sleep medication. Methods. A cross-sectional study of 140 consecutive T2DM outpatients, ages 40-65, glycohemoglobin HbA1c goal≤7. We searched for variables (including HbA1c) significantly associated with short (<6 hours) or long (>8 hours) SD, in comparison to intermediate SD (6-8 hours). Results. Higher HbA1c levels increased the chance of belonging to the group that sleeps <6 hours (p≤0.001). Better sleep quality, nocturnal diuresis, and morningness increased the chance of belonging to the group that sleeps >8 hours (p<0.05). Conclusions. There is an independent association between short SD and elevated HbA1c, in real-world T2DM outpatients. Future interventional studies could evaluate weather consistent, long-term sleep extension, from <6 hours to 7–9 hours per 24 hours, improves GC in T2DM outpatients.


Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 137-LB ◽  
Author(s):  
NEHA KARAJGIKAR ◽  
KARLA B. DETOYA ◽  
JANICE N. BEATTIE ◽  
STACEY J. LUTZ-MCCAIN ◽  
MONIQUE Y. BOUDREAUX-KELLY ◽  
...  

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 90-LB
Author(s):  
SANJAY K. BAJPAI ◽  
RADHIKA NAIR ◽  
TICH CHANGAMIRE ◽  
RICHARD SHEER ◽  
QIANQIAN WANG ◽  
...  

2017 ◽  
Vol 5 (1) ◽  
pp. e000431 ◽  
Author(s):  
Martin Fried ◽  
Karin Dolezalova ◽  
Adam P Chambers ◽  
Elliott J Fegelman ◽  
Robin Scamuffa ◽  
...  

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Xiaowen Zhang ◽  
Jie Sun ◽  
Wenqing Han ◽  
Yaqiu Jiang ◽  
Shiqiao Peng ◽  
...  

Objective. Type 2 deiodinase (Dio2) is an enzyme responsible for the conversion of T4 to T3. The Thr92Ala polymorphism has been shown related to an increased risk for developing type 2 diabetes mellitus (T2DM). The aim of this study is to assess the association between this polymorphism and glycemic control in T2DM patients as marked by the HbA1C levels.Design and Methods.The terms “rs225014,” “thr92ala,” “T92A,” or “dio2 a/g” were used to search for eligible studies in the PubMed, Embase, and Cochrane databases and Google Scholar. A systematic review and meta-analysis of studies including both polymorphism testing and glycated hemoglobin (HbA1C) assays were performed.Results. Four studies were selected, totaling 2190 subjects. The pooled mean difference of the studies was 0.48% (95% CI, 0.18–0.77%), indicating that type 2 diabetics homozygous for the Dio2 Thr92Ala polymorphism had higher HbA1C levels.Conclusions. Homozygosity for the Dio2 Thr92Ala polymorphism is associated with higher HbA1C levels in T2DM patients. To confirm this conclusion, more studies of larger populations are needed.


Sign in / Sign up

Export Citation Format

Share Document